Trial Profile
Phase II trial of oregovomab + poly ICLC in women with ovarian cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2014
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Poly ICLC (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 04 Feb 2014 New trial record